Bcr-Abl tyrosine kinase (TK) inhibitors are promising therapeutic agents for Bcr-Abl-positive (Bcr-Abl þ ) leukemias. Although they are known to promote caspase-mediated apoptosis, it remains unclear whether caspase-independent cell death-inducing mechanisms are also triggered. Here we demonstrated that INNO-406, a second-generation Bcr-Abl TK inhibitor, induces programmed cell death (PCD) in chronic myelogenous leukemia (CML) cell lines through both caspase-mediated and caspaseindependent pathways. The latter pathways include caspase-independent apoptosis (CIA) and necrosis-like cell death (CIND), and the cell lines varied regarding which mechanism was elicited upon INNO-406 treatment. We also observed that the propensity toward CIA or CIND in cells was strongly associated with cellular dependency on apoptosome-mediated caspase activity. Cells that undergo CIND have a high apoptosome activity potential whereas cells that undergo CIA tend to have a lower potential. Moreover, we found that INNO-406 promotes autophagy. When autophagy was inhibited with chloroquine or gene knockdown of beclin1 by shRNA, INNO-406-induced cell death was enhanced, which indicates that the autophagic response of the tumor cells is protective. These findings suggest new insights into the biology and therapy of Bcr-Abl þ leukemias.
Chronic myelogenous leukemia (CML) is caused by the specific chromosomal aberration t (9;22) that is known as the Philadelphia (Ph)-chromosome. This results in Bcr-Ablpositive (Bcr-Abl þ ) cells that bear the constitutively active Bcr-Abl tyrosine kinase (TK), which is the product of the Ph-chromosome and which drives leukemogenesis.
1,2 TK inhibitors that bind to the Abl TK active site in Bcr-Abl and thereby shut down Bcr-Abl signaling have been developed. These drugs have proved to be highly promising in CML therapy as they induce Bcr-Abl þ leukemic cell death, principally through the mitochondria-mediated intrinsic apoptosis pathway. [3] [4] [5] One such TK inhibitor is imatinib mesylate (Gleevect; Glivect; formerly STI571), which has been shown to effectively treat Ph þ leukemias, including CML and Ph þ acute lymphoblastic leukemia (ALL). 6, 7 Indeed, the development of imatinib dramatically altered the first-line therapy for CML. However, a small percentage of CML and Ph þ ALL patients, particularly those with advanced-phase disease, are refractory to imatinib therapy or suffer relapses. 7, 8 To overcome resistance to imatinib, we recently developed INNO-406 (formerly NS-187), which is a specific dual Bcr-Abl/Lyn inhibitor that kills Bcr-Abl þ cells 25-55 times more effectively than imatinib in vitro and at least 10 times more effectively in vivo. 9 A decade of intensive research has revealed several mechanisms that induce programmed cell death (PCD). These mechanisms can be caspase-dependent or caspaseindependent. The latter category include caspase-independent apoptosis (CIA), which employs mitochondrial molecules other than cytochrome (cyt) c, as well as other modes of cell death such as autophagic cell death, mitotic catastrophe, or caspase-independent necrosis-like cell death (CIND). [10] [11] [12] [13] We have reported that imatinib induces CIND in Bcr-Abl þ leukemias. 14 We and others have also elucidated how Bcr-Abl TK inhibitors initiate apoptosis in Bcr-Abl þ leukemias (by engaging pro-apoptotic BH3-only proteins such as Bim). 5 However, the events that take place after mitochondrial outer membrane permeabilization (MOMP) are yet to be fully defined, although caspase activity has been suggested to be essential for this process. 15, 16 Here we investigated how Bcr-Abl þ leukemic cell death is executed after MOMP when Bcr-Abl signaling is blocked by INNO-406 treatment. As observed previously, 11, 17, 18 we found that INNO-406 induces caspase-dependent apoptosis in Bcr-Abl þ leukemic cell lines and patient-derived Bcr-Abl þ leukemic cells. However, we also found that under caspaseinactive conditions in vitro, INNO-406 triggers CIA or delayed CIND, depending on the cell clone. Significantly, CIA was favored as the PCD mechanism when the potential of the cyt c-induced apoptosome to activate caspase in the cell was low, whereas CIND was triggered in cells that had a high apoptosome potential. These observations suggest that drugs such as INNO-406 that can activate caspase-independent PCD mechanisms may be highly useful for the treatment of cancers that show impaired caspase-dependent apoptosis. Treatment with anticancer agents, including TK inhibitors, has been shown to induce cellular autophagy in Bcr-Abl þ leukemias. 19 It has been speculated that this autophagy may either be a type-2 PCD process (autophagic cell death) or a mechanism that protects the cell in energy-insufficient conditions. [20] [21] [22] [23] In our study here, we also observed autophagy in the INNO-406-treated leukemic cells in caspase-inactive conditions, especially those undergoing CIND. However, experiments blocking autophagy by employing chloroquine (CQ), 3-methyladenine (3-MA) and short hairpin (sh) RNA knockdown of beclin1 revealed that the autophagy induced by INNO-406 is likely to be a cell-protective response. That INNO-406 therapy induces autophagy provides new insights into the biology and treatment of Bcr-Abl þ leukemias. (Figure 2d and data not shown), we next examined whether blocking caspase activity would inhibit INNO-406-induced cell death. Although caspase-3 activity was effectively blocked by zVAD-fmk (zVAD), a pan-caspase inhibitor pretreatment (Figure 2d and data not shown), it failed to completely abolish the INNO-406-induced cell death (Figures 1b and 2a) . This was true for all the cell lines we tested but the degree to which zVAD inhibited INNO-406-induced cell death differed depending on the cell line. Indeed, the cell lines could be divided into two types depending on how fast INNO-406 induced cell death in the presence of zVAD: the K562, KT-1 and BV173 lines showed a marked delay in cell death whereas the cell death of the MYL and Ba/F3/bcr-abl/wt lines was only marginally retarded ( Figure 1b) . Thus, INNO-406 can induce cell death by both caspase-mediated and caspase-independent pathways, and the dependence on caspase activity varies depending on the leukemic cell clone.
Results

INNO-406 induces
In the caspase-inactive condition, INNO-406 kills Bcr-Abl þ leukemic cell lines by two distinct mechanisms. As indicated above, the INNO-406-induced cell death that took place when caspase activity was intact was shown to be apoptosis, as determined by the presence of typical morphologic changes (such as cell shrinkage, nuclear condensation and nuclear fragmentation) and DNA fragmentation (Figure 2b and c) , followed by necrotic changes, which are morphologically characterized by cell swelling or rupture of cytoplasmic membrane, so-called 'secondary necrosis' (Figure 1civ and diii) . This is consistent with previous observations. 4, 14 Next we investigated the cell death pathways that are induced in each cell line by INNO-406 under caspase-inactive conditions. We found that zVAD-pretreated and INNO-406-treated K562, KT-1 and BV173 cells (i.e. the three cell lines whose killing by INNO-406 was strongly inhibited by zVAD pretreatment) underwent cell death associated with morphologic changes that are inconsistent with apoptosis but consistent with CIND, namely, the presence of cell shrinkage and non-fragmented nuclei with partial condensations (Figure 1c and data not shown). 12, 15, 19 These changes were not accompanied by DNA fragmentation or the accumulation of subG1 cells (Figure 2b) . Thus, the cell death mechanism utilized by K562, KT-1 and BV173 is distinct from caspase-dependent apoptosis and is likely to be CIND (Figure 2b ). In contrast, MYL and Ba/F3/bcr-abl/wt exhibited a typical apoptotic appearance and DNA fragmentation in both the presence and absence of caspase activity (Figures 1d and 2c) , which indicates that INNO-406 induced CIA in these cell lines. Significantly, the CIND and CIA mechanisms utilized by the lines after co-treatment with INNO-406 and zVAD were both blocked by the overexpression of Bcl-2 protein (Figure 2e and data not shown). This indicates that both pathways are mitochondria-mediated PCD ( Table 1) .
Ability of INNO-406 to induce CIA and CIND is associated with low and high apoptosome-mediated caspase activation potential, respectively. We examined 'the apoptosome activity potential', which is the intrinsic potential of the cells to activate caspase in a cyt c-induced apoptosome-mediated manner. 24 When the leukemic cell lines were tested for this parameter, we found that those that undergo CIND upon INNO-406 plus zVAD co-treatment tend to have a high apoptosome activity potential whereas those lines that undergo CIA tend to have a lower potential (Figure 3a) . Expression levels of apoptosome components (apoptotic protease-activating factor-1; Apaf-1, cyt c and caspase-9) and caspase-3 proteins varied among the five cell lines, irrespective of apoptosome activity. Moreover, the level of the X-linked inhibitor of apoptosis protein (XIAP), which was reported as a suppressor of apoptosome activation, 25 was almost equivalent (Figure 3b ). When we tested nine freshly isolated leukemic cell samples from BcrAbl þ leukemia patients, we found that they also had either low or high apoptosome activity potential (Figure 3c ). These results indicate that leukemic cells that produce a CIND response upon INNO-406 treatment under caspase-inactive conditions have a high apoptosome activity potential, whereas a CIA response is associated with a low potential, and moreover, the PCD response triggered by INNO Figure 2A) . INNO-406 alone induced the classical features of apoptosis, namely, the presence of darkened, fragmented nuclei. In contrast, cells undergoing CIND exhibited dispersed foci of chromatin condensation, heterochromatin and darkened nuclei. Significantly, they also exhibited extensive cytoplasmic vacuolation, autophagosomes and autophagic vacuoles containing membrane whorls, all of which seemed to consist with autophagic response.
To confirm that zVAD-pretreated and INNO-406-treated leukemic cells undergo autophagy, we used western blotting (WB) analysis to detect isoforms of the Light chain 3 (LC3)-II membrane protein, which is only present when cells form an autophagosome. 26 INNO-406-induced autophagy protects cells from cell death. To ascertain the role played by INNO-406-induced autophagy in caspase-inactive conditions, we sought to block autophagy by using CQ. CQ is a lysosomotropic drug that raises the intralysosomal pH and impairs autophagic protein degradation and is frequently used to inhibit autophagy. 20, 27 When K562, KT-1 and BV173 were tested, CQ treatment significantly enhanced the cell death induced by treatment with INNO-406 both alone and in combination with zVAD ( Figure 6A and B) , the mice were treated with INNO-406 (or vehicle). In the spleen and bone marrow (BM) of the INNO-406-treated mice, we found dying cells with abnormal nuclear structures (Figure 6a and b) such as the apoptotic bodies, fragmented nuclei, or condensed necklace-like nuclei that characterize the early stage of nuclear fragmentation that takes place during apoptotic execution, 28 and also CIND-like cells. These dying cells were rarely observed in untreated CIA, caspase-independent apoptosis; CIND, caspase-independent necrosis-like cell death; NE, not examined a The speed of cell death execution with zVAD pretreatment was compared with the speed of cell death execution without zVAD (Figure 1b) Cell death and autophagy of Ph þ leukemias Y Kamitsuji et al mice (data not shown) and proved to be the transplanted human leukemic cells, as determined by their reactivity to anti-human CD45 antibody (Figure 6a and b) . Notably, these cells were not always reactive with the antibody against cleaved caspase-3 ( Figure 6c ) and cleaved caspase-9 (Supplementary Figure 6C) . The percentage of cleaved caspase-3-negative cell of all dying cells in human Bcr-Abl þ leukemic cells xenografted mouse followed by INNO-406 treatment was 54% (spleen) and 71% (BM) (Figure 6c ), which suggest that caspase-3 and -9 activation is not necessary for the ability of INNO-406 to induce patient-derived leukemic cells to undergo cell death in vivo, or rather caspase-independent cell death is a major contributor to the in vivo response to INNO-406.
Discussion
Here we investigated the cell death mechanism that is elicited in Bcr-Abl þ leukemias by the Bcr-Abl TK inhibitor INNO-406. It was previously believed that Bcr-Abl TK inhibitors induce Bcr-Abl þ leukemias to undergo caspase-mediated apoptosis, mainly through mitochondria-mediated intrinsic apoptosis. 15 , 16 Indeed, we found in our study that INNO-406 induced the leukemic cells we tested to become apoptotic and that this was p53-independent ( Supplementary Figure 1) , and accompanied with caspase activation. However, we then found by pretreating the cells with the pan-caspase inhibitor zVAD that INNO-406 can also induce two distinct mechanisms of caspase-independent PCD, namely, delayed CIND or CIA. Notably, the leukemic cell lines varied regarding which of these alternative cell death pathways were triggered by INNO-406, as K562, KT-1 and BV173 underwent CIND whereas MYL and Ba/F3/bcr-abl/wt died by CIA (Table 1) .
These observations are of interest because they suggest that drugs such as INNO-406 may be useful in situations where the normal caspase-dependent apoptotic response to antitumor drugs has become impaired. This may happen if caspase becomes inactivated, which has been shown to occur in cancer cells by various mechanisms. These include the endogenous expression of inhibitors of apoptosis proteins (IAPs) such as XIAP. 29 Indeed, the expression of the IAP survivin has been linked to CML disease progression and apoptosis resistance, although it remains unclear whether this molecule truly functions as a caspase inhibitor. Caspase pathways can be inactivated by mutations, energy depletion, nitrative/oxidative stress, or the simultaneous activation of other proteases. 13, 30 Procaspase-9 activation within the apoptosome are also inhibited by release of low mass iron by lysosomal rupture. 31 Thus, that INNO-406 can trigger caspase-independent PCD as well as caspase-dependent apoptosis may point to new therapeutic avenues for Bcr-Abl þ leukemias. These observations may have ramifications for the treatment of other cancerous diseases as well.
As previously reported, INNO-406 shuts down Bcr-Abl and upregulates several BH3-only proteins, such as Bim, Bad, Bmf and Bik, 32 followed by MOMP, which is known as 'the point of no-return' for cell death commitment. 10, 33 As INNO-406 inhibits Bcr-Abl signaling as imatinib does, these events probably occur through shutdown of the downstream of Bcr-Abl signaling pathway, signal transducer and activator of transcription and phosphoinositide-3-kinase (PI3K)/Akt pathways. MOMP induces the release of toxic mitochondrial molecules such as cyt c into the cytosol. Cyt c forms a complex with Apaf-1 and pro-caspase-9 that is called the 'apoptosome'. This complex first promotes caspase-9 processing and then amplifies the proteolytic activities of the downstream caspase cascades. 34 It was recently observed that tumor cells vary in terms of their apoptosome activity potential, and that inactivation of the apoptosome is a cause of chemoresistance and oncogenic transformation. 24, 35, 36 The Cell death and autophagy of Ph þ leukemias Y Kamitsuji et al expression of XIAP, and defective p53 molecules have been reported to inhibit the apoptosome. 24, 37 It is believed that the natural cell death pathways are altered in apoptosomedefective cells. Therefore, to overcome chemoresistance, it may be useful to develop agents that can trigger another cell death pathway, such as a caspase-independent pathway. 24 However, it remains unclear how the cell death patterns are altered in apoptosome-defective tumor cells. Here, we show for the first time that low-potential apoptosome activity in BcrAbl þ leukemic cells is associated with a predisposition to generate a CIA response to INNO-406, whereas a high potential apoptosome activity is associated with a tendency to produce a CIND response. We reasoned that INNO-406 induces CIND in some leukemic cell lines but CIA in others because these cell lines vary in their degree of clonal transformation, in particular with regard to transformation events that affect apoptosome activity. It should be noted that the CML cell lines we used here were all derived from patients with the most advanced clinical phase of CML (CML-BC). The cells from these patients are thus likely to have experienced a high degree of clonal evolution involving the acquisition of various genetic mutations. Indeed, in the Bcr-Abl þ leukemic cell lines that had a high apoptosome activity potential, INNO-406-induced apoptotic cell death was effectively protected by zVAD, which suggests the high dependency on apoptosomemediated caspase apoptotic cell death pathway (Figures 1b, c  and 3a) . Consistent with this was that the zVAD-mediated caspase inhibition had only a marginal effect on the cell lines with lower apoptosome activity, which rapidly entered CIA upon INNO-406 treatment (Figures 1b, d and 3a) . Cell death and autophagy of Ph þ leukemias Y Kamitsuji et al the key mediator of this CIA, we examined Omi/Htra2 and apoptosis-inducing factor (AIF). Omi/Htra2 was not released into the cytosol, and AIF was not transferred to the nucleus (data not shown), so that these mediators were not related with this CIA.
Significantly, the intrinsic apoptosome-mediated caspase-3 activation potential in patient-derived Bcr-Abl þ leukemic cells also varied (Figure 3c ). Although it remains unclear why such differences in apoptosome activity potentially exist, these observations suggest that different cell types may vary in their dependence on the caspase-mediated pathway for apoptosis, and that this diversity may underlie the mode of caspaseindependent PCD that is triggered by INNO-406 upon caspase inactivation. It should also be noted that when we xenografted NOD/SCID mice with Bcr-Abl þ leukemic cells from various CML/ALL patients, INNO-406 successfully induced cell death in the leukemic cells even though caspase was not activated in many cases (Figure 6c ). Recent reports also support the concept of caspase-independent cell death in vivo. 38, 39 This observation demonstrates that caspase- Cell death and autophagy of Ph þ leukemias Y Kamitsuji et al independent cell death may play an important role in the clinical setting. These observations together also suggest that previous studies on CML cell lines may have overestimated the role caspases play in the apoptosis induced by Bcr-Abl TK inhibitors.
Prior studies have led to conflicting views regarding the role played by autophagy. In some settings, it has been reported as a type-2 PCD process (autophagic cell death) but in others it appears to serve as a mechanism that protects the cell in energy-insufficient conditions. [20] [21] [22] [23] 25 In our study, we found that cells undergoing INNO-406-induced CIND showed pronounced autophagy (Figure 4, Supplementary Figure 2 and data not shown) whereas the cells undergoing CIA showed more limited autophagy, which was detected only by LC3-II (Supplementary Figure 2B) . Thus, autophagy appears to play a significant role in CIND but not in CIA. This led to the question, does autophagy underlie the CIND cell death process or is it a protective response? To answer this question, we sought to block autophagy by CQ, 3-MA 20, 27 and shBeclin1 RNA transfection. Autophagy inhibition significantly enhanced cell death in the CIND-prone cell lines rather than reducing the CIND response to INNO-406 Supplementary Figures 3 and 4) . Thus, INNO-406-induced autophagy may be a protective process that is elicited by the cell during the course of INNO-406-induced CIND. It is possible that as the shutdown of Bcr-Abl signaling represents a sort of energy crisis for Bcr-Abl þ leukemias, the activation of autophagy may provide the nutrients necessary for leukemic cells to survive in this scenario. Thus, the pathways that promote autophagy may constitute a novel therapeutic target in CML, particularly for those leukemias that die by CIND in caspase-inactive conditions.
In conclusion, we show that the blockade of Bcr-Abl signaling in Bcr-Abl þ leukemic cells potently induces not just caspase-mediated apoptosis but also the caspase-independent PCD mechanisms, CIND and CIA. Different leukemia cell clones vary in the degree to which caspase is involved in INNO-406-induced PCD as well as in the caspase-independent PCD mechanism that is triggered by INNO-406 in caspase-inactive conditions. Autophagy is likely to serve as a cell preservation system that is activated in Bcr-Abl þ leukemias when Bcr-Abl signaling is blocked and thus may be a novel therapeutic target in CML.
Materials and Methods
Cells and reagents. The human leukemic cell lines K562, KT-1, BV173 and MYL were all derived from CML-BC patients. 40 Ba/F3/bcr-abl/wt, which expresses wild-type Bcr-Abl, was generated from the murine hematopoietic cell line Ba/F3 as previously described.
9 K562 and MYL sublines that overexpressed human Bcl-2 protein were generated by electroporation followed by WB screening using an antihuman Bcl-2 antibody (Bcl-2-100, Upstate, Lake Placid, NY) to detect high exogenous cytoplasmic Bcl-2 protein levels. 5 All cells were maintained at 371C under 5% CO 2 in RPMI-1640 containing 2 mM L-glutamine, 10% heat-inactivated fetal calf serum (Hyclone, UT) and 1% penicillin/streptomycin antibiotic mixture. INNO-406 was synthesized by Nippon Shinyaku Co. Ltd (Kyoto, Japan). zVAD was purchased from Peptide Institute (Osaka, Japan). PI, CQ and 3-MA were purchased from Sigma Aldrich (St Louis, MO). INNO-406 and zVAD were dissolved in dimethyl sulfoxide and stored at -20 1C. PI and CQ were dissolved in phosphate-buffered saline and stored at 4 1C. 3-MA was dissolved directly into RPMI-1640. zVAD was used at 50 mM, CQ was used at 10 mM for K562 and at 5 mM for KT-1, BV713, MYL and Ba/F3/bcr-abl/wt, and 3-MA was used at 10 mM. The cells were preincubated with zVAD, CQ and 3-MA for 90 min.
Primary Bcr-Abl þ leukemic cell samples. Studies with human samples were approved by the Ethical Board of the Kyoto University. BM or PB samples were obtained from Bcr-Abl þ leukemia patients with informed consent. More than 90% of the leukocytes in the samples were Ph þ (as determined by interphase FISH analysis of the presence of the bcr-abl fusion gene). The mononuclear cell fraction of the samples was isolated by conventional Ficoll-Paque (Amersham, Uppsala, Sweden) density gradient centrifugation.
Cell death assessment and determination of mitochondrial transmembrane potential (Dwm). Cell death was defined by the intracellular incorporation of PI, while the mitochondrial transmembrane potential (Dcm) was measured by FACSCalibur (Becton Dickinson (BD), Franklin Lakes, NJ) analysis after DiOC6(3) (Molecular Probes, Eugene, OR) staining as described. 14 Morphologic evaluation by light microscopy and electron microscopy. Cells were subjected to cytospin and stained with a Diff-Quick kit (International Reagents, Kobe, Japan), and then examined by light microscopy . A minimum of 400 cells was scored for each sample, and the percentage of each morphologic type was determined. Cells were also prepared for electron microscopy analysis with a Hitachi H-7000 electron microscope (Hitachi, Tokyo, Japan) as described previously.
14 Assessment of internucleosomal DNA fragmentation and DNA content. Internucleosomal DNA fragmentation was analyzed by using ApopLadder Ex (Takara, Shiga, Japan). For DNA content analysis, the cells were fixed with ice-cold 70% ethanol and stained with PI. The frequency of subG1 cells was determined by using CellQuest software (BD).
Immunofluorescent staining analysis. Cells were fixed with 4% paraformaldehyde on a glass slide, blocked with 20% Block Ace Powder (Dainippon Sumitomo Pharma, Osaka, Japan) with 0.005% saponin (Sigma) and stained with anti-LC3 antibody (a kind gift from Professor T Yoshimori, Osaka University, Japan) 26 followed by secondary staining with FITC-conjugated immunoglobulin G (IgG; Santa Cruz Biotechnology, Santa Cruz, CA).
Western blot analysis. Western blot analysis (WB) was performed as described previously. 32 Antibodies against b-tubulin (Sigma), b-actin (Sigma), caspase-3, cleaved caspase-3, caspase-9 (Cell signaling Technology, Beverly, MA), LC3, Apaf-1 (Epitomics Inc, Burlingame, CA), cyt c (BD Pharmingen, San Diego, CA), XIAP (MBL, Nagoya, Japan), p53, c-Abl (Santa Cruz), phosphotyrosine (Upstate) or Beclin1 (Novus Biologicals, Littleton, CO) were used.
Measurement of caspase activity. Caspase-3 activity in untreated or INNO-406-treated cells was measured by using a Caspase Fluorometric Protease Assay Kit (MBL) as previously described. 14 The intrinsic potential in CML cell lines of cyt c-induced caspase-3 activation (i.e., the apoptosome activity potential) was also examined as described elsewhere. 24 Briefly, cytosolic extracts of untreated cells were incubated with 10 mM bovine cyt c plus 1 mM dATP (Sigma) for 1 h and then incubated with 10 mM acetyl-Asp-Glu-Val-Asp-(4-metyl-coumaryl-7-amide) (DEVD-MCA) at 371C for 1 h. The release of amino-4-methylcoumarin was monitored by using the Wallac ARVO SX FL 1420 Multilabel Counter (excitation, 380 nm; emission, 460 nm) (PerkinElmer Life Sciences, Boston, MA).
shRNA transfection. K562 cells were transfected with SureSilencing shRNA plasmid specifically targeting beclin1 RNA with the resistance gene for puromycin (SuperArray, Frederick, MD) using Amaxa nucleofector with solution V, protocol T-03 (Amaxa Biosystems, Gaithersburg, MD). Transfected cells were selected by 5 mg/ml puromycin, and were examined for Beclin1 protein expression by WB analysis.
Mouse model for CML. Male NOD/SCID mice (6-8 weeks of age) were sublethally irradiated (2 Gy) and 3 Â 10 6 cells from Ph þ CML-BC patients were transplanted intravenously into the tail vein as previously described. 9 The engraftment of the transplanted leukemic cells was certified by flow cytometric analysis that examined the expression of human CD45 in the murine PB. Successfully engrafted mice were randomized into control and treated groups (two mice in each group), and treated with INNO-406 (3 mg per body) or vehicle (0.5% methylcellulose) and then sacrificed on the next day. Their BM and spleen were subjected to histological analyses. The experiment was done twice. FITC-conjugated human CD45 and PE-conjugated mouse CD45 antibodies (BD Pharmingen) were used for flow cytometric analysis, and antibodies against cleaved caspase-3, cleaved caspase-9 (Cell Signaling Technology) and human CD45 (Sigma) were utilized for IHC studies.
